Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate‐to‐severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the European Academy of Dermatology and Venereology

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jdv.14314PMID 28485816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta‐analysis of Psonet registries

  2017cited by this paper
• Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development

  2016cited by this paper
• Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

  2016cited by this paper
• Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

  2015cited by this paper
• Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.

  2015cited by this paper
• Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry

  2015cited by this paper
• Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

  2015cited by this paper
• Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry

  2015cited by this paper
• Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris

  2015cited by this paper
• Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

  2015cited by this paper
• ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

  2014cited by this paper
• Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

  2014cited by this paper
• Factors associated with withdrawal of the anti‐TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry

  2014cited by this paper
• Drug survival rates in patients with psoriasis after treatment with biologics

  2013cited by this paper
• Survival rate of antitumour necrosis factor‐α treatments for psoriasis in routine dermatological practice: a multicentre observational study

  2013cited by this paper
• Long‐term safety of biologics in the treatment of moderate‐to‐severe plaque psoriasis: review of current data

  2012cited by this paper
• Biologics for psoriasis: current evidence and future use

  2012cited by this paper
• Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.

  2012cited by this paper
• Drug survival rates of biologic treatments in patients with psoriasis vulgaris

  2012cited by this paper
• Adverse effects of biologics: a network meta-analysis and Cochrane overview.

  2011cited by this paper
• BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report

  2011cited by this paper
• Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

  2011cited by this paper
• [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].

  2011cited by this paper
• A new era in the management of psoriasis? The biologics: facts and controversies.

  2010cited by this paper
• British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

  2009cited by this paper
• The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal.

  2009cited by this paper
• Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

  2008cited by this paper
• Prevalence of psoriasis in Spain (Epiderma Project: phase I)

  2001cited by this paper

• Registro BIOBADADERM de la AEDV: 15 años de aportaciones a la seguridad de los tratamientos para la psoriasis.

  2025cites this paper
• AEDV Biobadaderm registry: 15 year-contribution to psoriasis therapy safety.

  2025cites this paper
• The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review

  2024cites this paper
• Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

  2023cites this paper
• Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study

  2023cites this paper
• Depression, anxiety and adjustment disorder among patients with psoriasis receiving systemic agents: A retrospective cohort study in Quebec, Canada

  2022cites this paper
• Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

  2021cites this paper
• Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model

  2021cites this paper
• Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex‐specific differences in psoriasis in the Czech Republic

  2021cites this paper
• Our ambition in a changing landscape of psoriasis treatments

  2020cites this paper
• Porque Suspendemos os Agentes Biológicos? Estudo Retrospectivo de 11 Anos

  2020cites this paper
• Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study

  2019cites this paper
• Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta‐analysis of observational and clinical studies

  2019cites this paper
• Update on Oral Therapy for Psoriasis

  2018cites this paper
• Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries

  2018cites this paper
• Review of European registries for psoriasis

  2018influential citation
• Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis)

  2018cites this paper
• Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis

  2018cites this paper
• Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

  2018cites this paper
• A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.

  2018cites this paper
• Acne and hidradenitis suppurativa

  2018cites this paper
• New biologics in psoriasis – progress and problems

  2017cites this paper